Edwards Lifesciences Corp Stock Performance
| EW Stock | USD 89.20 1.08 1.20% |
On a scale of 0 to 100, Edwards Lifesciences holds a performance score of 12. The firm shows a Beta (market volatility) of 0.73, which means possible diversification benefits within a given portfolio. As returns on the market increase, Edwards Lifesciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Edwards Lifesciences is expected to be smaller as well. Please check Edwards Lifesciences' potential upside, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether Edwards Lifesciences' price patterns will revert.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Edwards Lifesciences Corp are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile basic indicators, Edwards Lifesciences showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.24) | Five Day Return (1.58) | Year To Date Return 19.47 | Ten Year Return 571.06 | All Time Return 6.5 K |
Last Split Factor 3:1 | Last Split Date 2020-06-01 |
1 | Disposition of 150 shares by Lippis Daniel J. of Edwards Lifesciences at 86.1 subject to Rule 16b-3 | 02/16/2024 |
2 | IQVIA Up 5.3 percent Since Last Earnings Report Can It Continue | 03/15/2024 |
3 | Disposition of 6320 shares by Lippis Daniel J. of Edwards Lifesciences at 88.78 subject to Rule 16b-3 | 03/18/2024 |
4 | Academy Award Winner Matthew McConaughey Narrates MacGillivray Freemans 3D Documentary for IMAX and Giant Screen Theaters Superhuman Body World of Medical Marve... | 03/26/2024 |
5 | Disposition of 7255 shares by Scott Ullem of Edwards Lifesciences at 36.75 subject to Rule 16b-3 | 04/01/2024 |
6 | Q4 2023 ReShape Lifesciences Inc Earnings Call Transcript | 04/02/2024 |
7 | Disposition of 16618 shares by Michael Mussallem of Edwards Lifesciences at 92.7 subject to Rule 16b-3 | 04/04/2024 |
8 | Disposition of 6320 shares by Daniel Lippis of Edwards Lifesciences at 88.78 subject to Rule 16b-3 | 04/05/2024 |
9 | Edwards Lifesciences exec sells over 1.3m in stock, buys 529k worth | 04/08/2024 |
10 | 1000 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today | 04/12/2024 |
| Begin Period Cash Flow | 772.6 M |
Edwards |
Edwards Lifesciences Relative Risk vs. Return Landscape
If you would invest 7,382 in Edwards Lifesciences Corp on January 17, 2024 and sell it today you would earn a total of 1,538 from holding Edwards Lifesciences Corp or generate 20.83% return on investment over 90 days. Edwards Lifesciences Corp is generating 0.3258% of daily returns and assumes 2.0493% volatility on return distribution over the 90 days horizon. Put differently, 18% of stocks are less risky than Edwards on the basis of their historical return distribution, and some 94% of all equities are expected to be superior in generating returns on investments over the next 90 days. Expected Return |
| Risk |
Edwards Lifesciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Edwards Lifesciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Edwards Lifesciences Corp, and traders can use it to determine the average amount a Edwards Lifesciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.159
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EW | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.05 actual daily | 18 82% of assets are more volatile |
Expected Return
| 0.33 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Edwards Lifesciences is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Edwards Lifesciences by adding it to a well-diversified portfolio.
Edwards Lifesciences Fundamentals Growth
Edwards Stock prices reflect investors' perceptions of the future prospects and financial health of Edwards Lifesciences, and Edwards Lifesciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Edwards Stock performance.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.39 % | ||||
| Current Valuation | 53.39 B | ||||
| Shares Outstanding | 601.93 M | ||||
| Price To Earning | 32.77 X | ||||
| Price To Book | 8.17 X | ||||
| Price To Sales | 9.05 X | ||||
| Revenue | 6 B | ||||
| Gross Profit | 4.3 B | ||||
| EBITDA | 1.53 B | ||||
| Net Income | 1.4 B | ||||
| Cash And Equivalents | 769 M | ||||
| Cash Per Share | 2.81 X | ||||
| Total Debt | 694.9 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.83 X | ||||
| Book Value Per Share | 11.06 X | ||||
| Cash Flow From Operations | 895.8 M | ||||
| Earnings Per Share | 2.30 X | ||||
| Market Capitalization | 54.34 B | ||||
| Total Asset | 9.36 B | ||||
| Retained Earnings | 8.99 B | ||||
| Working Capital | 2.84 B | ||||
| Current Asset | 2.05 B | ||||
| Current Liabilities | 476.2 M | ||||
About Edwards Lifesciences Performance
To evaluate Edwards Lifesciences Corp Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Edwards Lifesciences generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Edwards Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Edwards Lifesciences Corp market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Edwards's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 309.03 | 324.48 | |
| Return On Tangible Assets | 0.18 | 0.1 | |
| Return On Capital Employed | 0.19 | 0.14 | |
| Return On Assets | 0.15 | 0.08 | |
| Return On Equity | 0.21 | 0.11 |
Things to note about Edwards Lifesciences Corp performance evaluation
Checking the ongoing alerts about Edwards Lifesciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Edwards Lifesciences Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 84.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from benzinga.com: 1000 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth This Much Today |
- Analyzing Edwards Lifesciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Edwards Lifesciences' stock is overvalued or undervalued compared to its peers.
- Examining Edwards Lifesciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Edwards Lifesciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Edwards Lifesciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Edwards Lifesciences' stock. These opinions can provide insight into Edwards Lifesciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Edwards Stock analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| CEOs Directory Screen CEOs from public companies around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Edwards Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edwards Lifesciences. If investors know Edwards will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edwards Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share 2.3 | Revenue Per Share 9.897 | Quarterly Revenue Growth 0.138 | Return On Assets 0.1225 |
The market value of Edwards Lifesciences Corp is measured differently than its book value, which is the value of Edwards that is recorded on the company's balance sheet. Investors also form their own opinion of Edwards Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Edwards Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edwards Lifesciences' market value can be influenced by many factors that don't directly affect Edwards Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edwards Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edwards Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edwards Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.